Abstract:In this study, the prognostic value and potential function of JAM2 in lung adenocarcinoma were analyzed by combining bioinformatics analysis, in vitro and in vivo experiments, and clinical specimens. Background Junctional adhesion molecule 2 (JAM2) plays a pivotal role in various biological processes, including proliferation, metastasis and angiogenesis, contributing to tumor progression. While previous studies have highlighted the polarizing functions of JAM2 in different cancer types, its specific role in lung adenocarcinoma (LUAD) remains unclear. Methods In this study, we harnessed multiple public databases to analyze the expression and prognostic significance of JAM2 in LUAD. Using the Linkedomics database, Matescape database and R package, we explored the associated genes, the potential biological functions and the impact of JAM2 on the tumor microenvironment. Our findings from public databases were further validated using real‐time quantitative PCR, western blot and immunohistochemistry. Additionally, in vitro experiments were conducted to assess the influence of JAM2 on LUAD cell proliferation, invasion, migration, apoptosis and epithelial–mesenchymal transition. Furthermore, we established a xenograft model to investigate the in vivo effects of JAM2 on tumorigenesis. Results Our results revealed a significant downregulation of JAM2 in LUAD, and patients with low JAM2 expression exhibited unfavorable overall survival outcomes. Functional enrichment analysis indicated that JAM2 may be associated with processes such as cell adhesion, extracellular matrix, cell junctions and regulation of proliferation. Notably, increased JAM2 expression correlated with higher tumor microenvironment scores and reduced immune cell abundance. Furthermore, overexpression of JAM2 induced apoptosis, suppressed tumor proliferation and exhibited potential inhibitory effects on tumor invasion and migration through the modulation of epithelial–mesenchymal transition. Additionally, in vivo experiments confirmed that JAM2 overexpression led to a reduction in tumor growth. Conclusion Overall, our study highlights the clinical significance of low JAM2 expression as a predictor of poor prognosis in LUAD patients. Moreover, JAM2 was found to exert inhibitory effects on various aspects of tumor progression. Consequently, JAM2 emerges as a promising prognostic biomarker and a potential therapeutic target for LUAD patients.

JAML overexpressed in colorectal cancer promotes tumour proliferation by activating the PI3K-AKT-mTOR signalling pathway

JAML Overexpression in Tumour Vascular Endothelial Cells Promotes Cancer Proliferation Via Angiogenesis Through VEGF Signalling Pathway Activation

JAML inhibits colorectal carcinogenesis by modulating the tumor immune microenvironment

Junctional Adhesion Molecule-Like Protein Promotes Tumor Progression and Metastasis via p38 Signaling Pathway in Gastric Cancer

Aberrantly Expressed Fra-1 by Il-6/Stat3 Transactivation Promotes Colorectal Cancer Aggressiveness Through Epithelial-Mesenchymal Transition

Junctional Adhesion Molecule-Like Protein (JAML) is Correlated with Prognosis and Immune Infiltrates in Lung Adenocarcinoma

ANGPTL1 Attenuates Colorectal Cancer Metastasis by Up-Regulating Microrna-138

Overexpression Of Jam-A In Non-Small Cell Lung Cancer Correlates With Tumor Progression

JAML promotes the antitumor role of tumor-resident CD8 + T cells by facilitating their innate-like function in human lung cancer

Identification and Validation of JAM-A as a Novel Prognostic and Immune Factor in Human Tumors

Junctional adhesion molecule-like protein promotes tumor progression via the Wnt/β-catenin signaling pathway in lung adenocarcinoma

Apelin13/APJ promotes proliferation of colon carcinoma by activating Notch3 signaling pathway.

JAM3 Functions As a Novel Tumor Suppressor and is Inactivated by DNA Methylation in Colorectal Cancer

JAM2 is a prognostic biomarker and inhibits proliferation, metastasis and epithelial–mesenchymal transition in lung adenocarcinoma

Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt/β-catenin signaling

LAMB3 promotes tumour progression through the AKT–FOXO3/4 axis and is transcriptionally regulated by the BRD2/acetylated ELK4 complex in colorectal cancer

GJA1 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Colorectal Cancer.

High Expression of JAM2 Indicates Better Prognosis and Immunotherapy Response in Breast Cancer

TAZ Expression As a Prognostic Indicator in Colorectal Cancer.

Inhibition of JAK1, 2/STAT3 Signaling Induces Apoptosis, Cell Cycle Arrest, and Reduces Tumor Cell Invasion in Colorectal Cancer Cells

LIM protein JUB promotes epithelial-mesenchymal transition in colorectal cancer.